(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.31%) $78.72
(-1.28%) $2.17
(0.06%) $2 332.60
(0.03%) $27.62
(0.74%) $972.05
(0.02%) $0.928
(0.13%) $10.84
(0.05%) $0.796
(0.00%) $91.35
Quarter results today
(bmo 2024-05-07)
Expected move: +/- 0.00%
-0.29% € 27.87
Live Chart Being Loaded With Signals
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed...
Stats | |
---|---|
Объем за сегодня | 778 869 |
Средний объем | 1.12M |
Рыночная капитализация | 15.70B |
EPS | €0 ( 2024-02-20 ) |
Дата следующего отчета о доходах | ( €0 ) 2024-07-31 |
Last Dividend | €0.920 ( 2023-05-18 ) |
Next Dividend | €0 ( N/A ) |
P/E | 44.24 |
ATR14 | €0.0150 (0.05%) |
Объем Корреляция
Fresenius SE & Co KGaA Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Fresenius SE & Co KGaA Корреляция - Валюта/Сырье
Fresenius SE & Co KGaA Финансовые показатели
Annual | 2023 |
Выручка: | €22.30B |
Валовая прибыль: | €5.06B (22.68 %) |
EPS: | €-1.050 |
FY | 2023 |
Выручка: | €22.30B |
Валовая прибыль: | €5.06B (22.68 %) |
EPS: | €-1.050 |
FY | 2022 |
Выручка: | €40.84B |
Валовая прибыль: | €10.73B (26.26 %) |
EPS: | €2.44 |
FY | 2021 |
Выручка: | €37.52B |
Валовая прибыль: | €10.31B (27.48 %) |
EPS: | €3.26 |
Financial Reports:
No articles found.
Fresenius SE & Co KGaA Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0.920 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.512 | 2000-06-09 |
Last Dividend | €0.920 | 2023-05-18 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 25 | -- |
Total Paid Out | €12.51 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.02 | -- |
Div. Sustainability Score | 6.12 | |
Div.Growth Potential Score | 2.36 | |
Div. Directional Score | 4.24 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SNW.DE | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
BZ7A.F | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
KRN.DE | Ex Dividend Knight | 2023-05-24 | Annually | 0 | 0.00% | |
UWS.DE | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% | |
DKG.DE | No Dividend Player | 2023-07-14 | Annually | 0 | 0.00% | |
NF4.DE | No Dividend Player | 2023-06-27 | Sporadic | 0 | 0.00% | |
4AB.DE | Ex Dividend Knight | 2023-10-12 | Quarterly | 0 | 0.00% | |
FMC1.DE | Ex Dividend Knight | 2023-07-24 | Semi-Annually | 0 | 0.00% | |
PRG.DE | Ex Dividend Knight | 2023-07-20 | Quarterly | 0 | 0.00% | |
AMG.DE | Ex Dividend Knight | 2023-08-17 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0187 | 1.500 | -0.374 | -0.561 | [0 - 0.5] |
returnOnAssetsTTM | -0.0131 | 1.200 | -0.437 | -0.525 | [0 - 0.3] |
returnOnEquityTTM | -0.0298 | 1.500 | -1.443 | -2.16 | [0.1 - 1] |
payoutRatioTTM | -2.07 | -1.000 | -10.00 | 10.00 | [0 - 1] |
currentRatioTTM | 1.342 | 0.800 | 8.29 | 6.63 | [1 - 3] |
quickRatioTTM | 0.729 | 0.800 | -0.419 | -0.335 | [0.8 - 2.5] |
cashRatioTTM | 0.245 | 1.500 | 9.75 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.350 | -1.500 | 4.17 | -6.26 | [0 - 0.6] |
interestCoverageTTM | 2.53 | 1.000 | -0.174 | -0.174 | [3 - 30] |
operatingCashFlowPerShareTTM | 7.91 | 2.00 | 7.36 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.90 | 2.00 | 7.05 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.833 | -1.500 | 6.67 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.233 | 1.000 | 9.45 | 9.45 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0554 | 1.000 | -0.892 | -0.892 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.281 | 1.000 | 9.55 | 9.55 | [0.2 - 2] |
assetTurnoverTTM | 0.702 | 0.800 | 8.65 | 6.92 | [0.5 - 2] |
Total Score | 6.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -26.50 | 1.000 | -2.78 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0298 | 2.50 | -0.927 | -2.16 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.90 | 2.00 | 8.03 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.29 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 7.91 | 2.00 | 7.36 | 10.00 | [0 - 30] |
payoutRatioTTM | -2.07 | 1.500 | -10.00 | 10.00 | [0 - 1] |
pegRatioTTM | 0.468 | 1.500 | -0.213 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.140 | 1.000 | 8.99 | 0 | [0.1 - 0.5] |
Total Score | 2.36 |
Fresenius SE & Co KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа